Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report

Pediatric glioblastoma multiforme is an uncommon and highly mortal brain cancer. New therapeutic treatments are being intensively investigated by researchers in order to extend the survival of patients. The immune checkpoint inhibitor nivolumab in the treatment of pediatric glioblastoma multiforme i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kartal, Ömer, Ataş, Erman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262382/
https://www.ncbi.nlm.nih.gov/pubmed/30404191
http://dx.doi.org/10.3390/medicina54050082
_version_ 1783375092978286592
author Kartal, Ömer
Ataş, Erman
author_facet Kartal, Ömer
Ataş, Erman
author_sort Kartal, Ömer
collection PubMed
description Pediatric glioblastoma multiforme is an uncommon and highly mortal brain cancer. New therapeutic treatments are being intensively investigated by researchers in order to extend the survival of patients. The immune checkpoint inhibitor nivolumab in the treatment of pediatric glioblastoma multiforme is currently under review; it is a human immunoglobulin G4 monoclonal antibody that works against the programmed cell death protein 1 receptor, designed to enhance an immunologic reaction against cancer cells. Herein, we describe the first report of a bilateral optic neuritis induced by nivolumab in a grade 4 glioblastoma multiforme patient.
format Online
Article
Text
id pubmed-6262382
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62623822018-12-05 Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report Kartal, Ömer Ataş, Erman Medicina (Kaunas) Case Report Pediatric glioblastoma multiforme is an uncommon and highly mortal brain cancer. New therapeutic treatments are being intensively investigated by researchers in order to extend the survival of patients. The immune checkpoint inhibitor nivolumab in the treatment of pediatric glioblastoma multiforme is currently under review; it is a human immunoglobulin G4 monoclonal antibody that works against the programmed cell death protein 1 receptor, designed to enhance an immunologic reaction against cancer cells. Herein, we describe the first report of a bilateral optic neuritis induced by nivolumab in a grade 4 glioblastoma multiforme patient. MDPI 2018-11-06 /pmc/articles/PMC6262382/ /pubmed/30404191 http://dx.doi.org/10.3390/medicina54050082 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Kartal, Ömer
Ataş, Erman
Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report
title Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report
title_full Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report
title_fullStr Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report
title_full_unstemmed Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report
title_short Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report
title_sort bilateral optic neuritis secondary to nivolumab therapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262382/
https://www.ncbi.nlm.nih.gov/pubmed/30404191
http://dx.doi.org/10.3390/medicina54050082
work_keys_str_mv AT kartalomer bilateralopticneuritissecondarytonivolumabtherapyacasereport
AT ataserman bilateralopticneuritissecondarytonivolumabtherapyacasereport

Ejemplares similares